These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 1261151)

  • 21. Pharmacokinetics of phenytoin and its metabolite, 4'-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin.
    Kim YC; Kang HE; Lee MG
    Biopharm Drug Dispos; 2008 Jan; 29(1):51-61. PubMed ID: 18022993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison on bioequivalence of four phenytoin preparations in patients with multiple-dose treatment.
    Tsai JJ; Lai ML; Yang YH; Huang JD
    J Clin Pharmacol; 1992 Mar; 32(3):272-6. PubMed ID: 1564132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The bioavailability of phenytoin.
    Gugler R; Fröscher W; Eichelbaum M; Hildenbrand G
    J Neurol; 1977 Oct; 216(3):155-62. PubMed ID: 72133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.
    Sandor P; Sellers EM; Dumbrell M; Khouw V
    Clin Pharmacol Ther; 1981 Sep; 30(3):390-7. PubMed ID: 7273603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.
    Crowley JJ; Koup JR; Cusack BJ; Ludden TM; Vestal RE
    Eur J Clin Pharmacol; 1987; 32(2):141-8. PubMed ID: 3582477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of a simplified method to determine bioavailability of an oral dose of phenytoin.
    Davis AL; Begg EJ; Kennedy MC; Graham GG
    J Pharmacokinet Biopharm; 1993 Apr; 21(2):195-208. PubMed ID: 8229680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of phenytoin on single and multiple oral doses of two dosage forms in normal subjects.
    Kohda Y; Nishihara K; Isozaki S; Saitoh Y; Nakagawa F; Tamura Z
    J Pharmacobiodyn; 1983 Jan; 6(1):46-55. PubMed ID: 6854522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation.
    Randinitis EJ; Buchanan RA; Kinkel AW
    Epilepsia; 1990; 31(4):458-64. PubMed ID: 2369880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.
    Heykants J; Hendriks R; Meuldermans W; Michiels M; Scheygrond H; Reyntjens H
    Eur J Drug Metab Pharmacokinet; 1981; 6(1):61-70. PubMed ID: 7250152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.
    Suthisisang C; Payakachat N; Chulavatnatol S; Towanabut S
    J Med Assoc Thai; 1998 Jan; 81(1):64-70. PubMed ID: 9470324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans.
    Jamerson BD; Donn KH; Dukes GE; Messenheimer JA; Brouwer KL; Powell JR
    Epilepsia; 1990; 31(5):592-7. PubMed ID: 2401249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chlorpropamide bioavailability and pharmacokinetics.
    Huupponen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):331-3. PubMed ID: 7263111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.
    Sawchuk RJ; Pepin SM; Leppik IE; Gumnit RJ
    J Pharmacokinet Biopharm; 1982 Aug; 10(4):383-91. PubMed ID: 7153871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.
    Bergan T; Thorsteinsson SB; Solberg R; Bjornskau L; Kolstad IM; Johnsen S
    Am J Med; 1987 Apr; 82(4A):97-102. PubMed ID: 3578334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
    Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sucralfate on phenytoin bioavailability.
    Hall TG; Cuddy PG; Glass CJ; Melethil S
    Drug Intell Clin Pharm; 1986; 20(7-8):607-11. PubMed ID: 3755676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food.
    Cacek AT
    Ther Drug Monit; 1986; 8(2):166-71. PubMed ID: 3726929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.